HUMA stock forecast, quote, news & analysis
Humacyte Inc is developing a commercial-stage biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine... Show more
Why Humacyte (HUMA) Stock Is Down -31% in the Last 30 Days
Key Takeaways
- HUMA fell roughly 31% over the trailing 30 days, from a close of $0.59 on September 21, 2026 to $0.406 on October 20, 2026.
- The decline extends a longer slide; over the trailing three months the stock is down about 39%.
- Barclays' initiation at Equal Weight with a $0.50 price target in early October added pressure to a stock already in a downtrend.
- Positive updates—including a 44% jump in hospitals ordering Symvess and a reiterated Buy from H.C. Wainwright—sparked only a brief rebound.
- Humacyte remains pre-profitability, reporting a second-quarter 2026 GAAP net loss of $36.8 million on revenue of $406,000.
Humacyte (HUMA) Company Overview and Market Position
Humacyte, Inc. is a commercial-stage regenerative-medicine and biotechnology company based in Durham, North Carolina. The company develops off-the-shelf, bioengineered human tissues using its proprietary platform. Its lead product, Symvess—an acellular tissue engineered vessel (ATEV)—was approved by the U.S. Food and Drug Administration in December 2024 for use as a vascular conduit in extremity arterial injury when urgent revascularization is needed and an autologous vein graft is not feasible.
Beyond its vascular-trauma indication, Humacyte is advancing the ATEV in late-stage trials for arteriovenous access in hemodialysis and peripheral artery disease, with additional preclinical work in coronary artery bypass grafts, pediatric heart surgery, and type 1 diabetes. Several programs carry FDA Regenerative Medicine Advanced Therapy (RMAT) and Fast Track designations. Investors follow the stock for its first-of-its-kind "off-the-shelf" bioengineered vessel and its expansion from a trauma niche into substantially larger dialysis and cardiovascular markets.
Humacyte (HUMA) Stock Price Performance: Last 30 Days vs. Quarter
HUMA closed at $0.59 on September 21, 2026 and ended at $0.406 on October 20, 2026, a decline of about 31%. The move was not linear: the shares drifted lower through early October, set an intraday low near $0.337 on October 14, then rebounded sharply on October 15 following a commercial update before giving back part of the gain.
Over the trailing three months the picture is weaker still. From a close near $0.67 in late July 2026, the stock has fallen roughly 39%, reflecting a sustained downtrend that predates the most recent 30-day window. The stock's 52-week range of roughly $0.34 to $1.90 underscores how far shares have come off earlier highs.
What Drove HUMA Stock Price in the Last 30 Days
Several verified developments shaped the recent move. In early October, Barclays initiated coverage with an Equal Weight rating and a $0.50 price target, a muted stance that weighed on sentiment at a time when the stock was already under pressure. The shares continued lower through the first half of October, reaching a closing low of $0.3541 on October 14.
On October 15, Humacyte reported that the number of hospitals ordering Symvess rose 44% during the third quarter, from 34 to 49 as of September 30, 2026, with new-hospital ordering increasing sequentially each month. The announcement drove a strong one-day rebound, and H.C. Wainwright subsequently reiterated its Buy rating on October 16. However, the bounce proved short-lived, and the shares faded back toward $0.40 in subsequent sessions, suggesting that persistent selling pressure and limited near-term conviction outweighed the positive commercial data.
What Drove HUMA Stock Performance Over the Last Quarter
The broader three-month decline reflects factors that have weighed on the stock for much of 2026. Humacyte is still scaling Symvess commercially while reporting operating losses—revenue of $406,000 and a GAAP net loss of $36.8 million in the second quarter—which keeps questions about cash runway and potential future financing at the center of the debate. A sharp selloff in mid-August, before the current 30-day window, established a lower base, and the shares have largely ground lower since.
At the same time, the company has continued to execute: it expanded its board of directors in late September and outlined plans for a supplemental Biologics License Application for the dialysis (AV access) indication as early as November 2026. Those milestones have not yet been enough to reverse the stock's downward bias.
Trending AI Robots
Tickeron's Trending AI Robots page highlights a curated selection of the platform's top-performing automated trading strategies. While Tickeron offers hundreds of AI-powered trading bots that trade thousands of tickers, only the most relevant and best-performing robots are featured in this section, making it a useful starting point for traders exploring algorithmic approaches. The bots vary widely in strategy, holding timeframe, and performance metrics, so it is worth reviewing each robot's approach to see whether it aligns with your own objectives. Exploring the current lineup can help you see which AI-driven strategies are generating attention in the market.
HUMA Stock Forecast Drivers: What Investors Should Watch Next
Looking ahead, several catalysts could move the shares. Humacyte's third-quarter earnings report, which will provide updated revenue and guidance on the Symvess launch, is a key event, and management has signaled it will discuss hospital adoption and growth plans on that call. Investors should also monitor the planned supplemental BLA submission for the AV-access indication and any late-breaking Phase 3 data presentations in dialysis. On the downside, cash-burn dynamics, potential financing needs, and analyst expectations remain important, alongside broad small-cap biotech sentiment. These are factors to monitor rather than recommendations.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Momentum Indicator for HUMA turns negative, indicating new downward trend
HUMA saw its Momentum Indicator move below the 0 level on September 25, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 93 similar instances where the indicator turned negative. In 84 of the 93 cases, the stock moved further down in the following days. The odds of a decline are at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
Following a 3-day decline, the stock is projected to fall further. Considering past instances where HUMA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 89%.
The Aroon Indicator for HUMA entered a downward trend on October 21, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where HUMA's RSI Indicator exited the oversold zone, 36 of 39 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 90%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 47 of 57 cases where HUMA's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 82%.
The Moving Average Convergence Divergence (MACD) for HUMA just turned positive on October 21, 2026. Looking at past instances where HUMA's MACD turned positive, the stock continued to rise in 34 of 40 cases over the following month. The odds of a continued upward trend are 85%.
Following a +2.52% 3-day Advance, the price is estimated to grow further. Considering data from situations where HUMA advanced for three days, in 196 of 241 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.
HUMA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 14 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 71 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.671) is normal, around the industry mean (2.988). P/E Ratio (-0.794) is within average values for comparable stocks, (-1.158). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (123.903) among similar stocks. P/S Ratio (52.083) is also within normal values, averaging (438.009).
The Tickeron Price Growth Rating for this company is 89 (best 1 - 100 worst), indicating slightly worse than average price growth. HUMA’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. HUMA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology